title: Modulation of the cortical processing of novel and target stimuli by drugs affecting glutamate and GABA neurotransmission.
abstract: In this double-blind, placebo-controlled study, we examined the effects of subanaesthetic doses of ketamine (an NMDA glutamate receptor antagonist) and thiopental (a GABA-A receptor agonist) on the event-related potential (ERP) correlates of deviant stimulus processing in 24 healthy adults. Participants completed three separate pharmacological challenge sessions (ketamine, thiopental, saline) in a counterbalanced order. EEG data were recorded both before and during each challenge while participants performed a visual 'oddball' task consisting of infrequent 'target' and 'novel' stimuli intermixed with frequent 'standard' stimuli. We examined drug effects on the amplitude and latency of the P300 (P3) component of the ERP elicited by target (P3b) and novel stimuli (P3a), as well as the N200 (N2) component elicited by both target and novel stimuli, and the N100 (N1) elicited by standard stimuli. Relative to placebo, both drugs reduced the amplitude of parietal P3b. While both drugs reduced parietal P3a and Novelty N2, ketamine also shortened P3a latency, reduced Novelty N2 amplitude more than thiopental, and increased frontal P3a amplitude relative to placebo. Overall, the data suggest that both the GABA-A and NMDA receptor systems modulate P3b and P3a. NMDA antagonism appears to lead to more varied effects on the neural correlates of novelty processing.
authors.affiliation: NIAAA Center for the Translational Neuroscience of Alcoholism and Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. toddw@lclark.edu
authors.forename: Todd D
authors.initials: TD
authors.lastname: Watson
authors.forename: Ismene L
authors.initials: IL
authors.lastname: Petrakis
authors.forename: Javon
authors.initials: J
authors.lastname: Edgecombe
authors.forename: Albert
authors.initials: A
authors.lastname: Perrino
authors.forename: John H
authors.initials: JH
authors.lastname: Krystal
authors.forename: Daniel H
authors.initials: DH
authors.lastname: Mathalon
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D002540:Cerebral Cortex / Q000187:drug effects* / Q000502:physiology; D004311:Double-Blind Method; D004569:Electroencephalography / Q000379:methods; D005071:Evoked Potentials / Q000187:drug effects / Q000502:physiology*; D005260:Female; D018757:GABA Modulators / Q000494:pharmacology*; D006801:Humans; D007649:Ketamine / Q000494:pharmacology; D008297:Male; D010147:Pain Measurement; D010364:Pattern Recognition, Visual / Q000502:physiology; D010775:Photic Stimulation / Q000379:methods; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D018080:Receptors, GABA-B / Q000378:metabolism*; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013223:Statistics as Topic; D013874:Thiopental / Q000494:pharmacology*; D055815:Young Adult
chemical_list: D018757:GABA Modulators; D018080:Receptors, GABA-B; D016194:Receptors, N-Methyl-D-Aspartate; D007649:Ketamine; D013874:Thiopental
references.citation: Cereb Cortex. 2005 Jun;15(6):749-59
references.pmid: 15537676
references.citation: Electroencephalogr Clin Neurophysiol. 1991 Feb;78(2):142-9
references.pmid: 1704837
references.citation: Psychophysiology. 2002 Mar;39(2):147-57
references.pmid: 12212663
references.citation: Cogn Affect Behav Neurosci. 2003 Mar;3(1):17-26
references.pmid: 12822595
references.citation: Psychol Bull. 2005 Jul;131(4):510-32
references.pmid: 16060800
references.citation: Int J Psychophysiol. 2006 May;60(2):172-85
references.pmid: 16510201
references.citation: Nature. 1996 Sep 19;383(6597):256-9
references.pmid: 8805701
references.citation: Schizophr Bull. 2007 Jul;33(4):848-52
references.pmid: 17567628
references.citation: Anesth Analg. 1991 Nov;73(5):612-8
references.pmid: 1952143
references.citation: Clin EEG Neurosci. 2006 Oct;37(4):309-14
references.pmid: 17073169
references.citation: Psychophysiology. 2003 Nov;40(6):914-23
references.pmid: 14986844
references.citation: J Cogn Neurosci. 2002 May 15;14(4):593-602
references.pmid: 12126500
references.citation: Neuroreport. 2005 Nov 28;16(17):1933-7
references.pmid: 16272882
references.citation: Neuropsychobiology. 1999;40(2):86-94
references.pmid: 10474063
references.citation: Arch Gen Psychiatry. 1994 Mar;51(3):199-214
references.pmid: 8122957
references.citation: Crit Rev Neurobiol. 2000;14(3-4):199-224
references.pmid: 12645958
references.citation: Psychopharmacology (Berl). 2007 Jul;192(4):511-9
references.pmid: 17318501
references.citation: Electroencephalogr Clin Neurophysiol. 1984 Feb;59(1):9-20
references.pmid: 6198170
references.citation: Electroencephalogr Clin Neurophysiol. 1975 Aug;39(2):131-43
references.pmid: 50210
references.citation: J Clin Neurophysiol. 1992 Oct;9(4):456-79
references.pmid: 1464675
references.citation: Biol Psychol. 2003 Oct;64(1-2):119-41
references.pmid: 14602358
references.citation: Psychiatry Clin Neurosci. 1999 Apr;53(2):185-7
references.pmid: 10459684
references.citation: Neuropsychopharmacology. 2000 Mar;22(3):293-302
references.pmid: 10693157
references.citation: Psychopharmacology (Berl). 2005 Apr;179(1):303-9
references.pmid: 15309376
references.citation: Brain Res Cogn Brain Res. 2005 Feb;22(2):221-31
references.pmid: 15653295
references.citation: Neuropsychopharmacology. 2004 Jun;29(6):1203-14
references.pmid: 15100698
references.citation: Int J Psychophysiol. 2006 Jan;59(1):8-14
references.pmid: 16253363
references.citation: Clin Neurophysiol. 2006 Aug;117(8):1638-40
references.pmid: 16798078
references.citation: Electroencephalogr Clin Neurophysiol. 1998 Feb;106(2):156-64
references.pmid: 9741777
references.citation: Clin Neurophysiol. 2007 Oct;118(10):2128-48
references.pmid: 17573239
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2003 Sep;27(6):1013-21
references.pmid: 14499319
references.citation: Brain Cogn. 2004 Oct;56(1):5-13
references.pmid: 15380870
references.citation: Brain Cogn. 2004 Nov;56(2):165-76
references.pmid: 15518933
references.citation: Behav Brain Res. 1990 Jul 9;39(2):187-95
references.pmid: 2167694
references.citation: Brain Topogr. 2003 Spring;15(3):141-52
references.pmid: 12705810
references.citation: Clin Neurophysiol. 2004 Apr;115(4):732-44
references.pmid: 15003751
references.citation: Clin Neurophysiol. 2007 May;118(5):1069-77
references.pmid: 17368096
references.citation: Acta Psychol (Amst). 1999 Apr;101(2-3):267-91
references.pmid: 10344188
references.citation: Electroencephalogr Clin Neurophysiol. 1983 Apr;55(4):468-84
references.pmid: 6187540
references.citation: Arch Gen Psychiatry. 2005 Sep;62(9):985-94
references.pmid: 16143730
references.citation: Prog Neuropsychopharmacol Biol Psychiatry. 2003 Sep;27(6):993-9
references.pmid: 14499316
references.citation: Physiol Behav. 2002 Dec;77(4-5):477-82
references.pmid: 12526986
references.citation: Electroencephalogr Clin Neurophysiol. 1975 Apr;38(4):387-401
references.pmid: 46819
references.citation: Biol Psychol. 1997 Aug 22;46(2):113-24
references.pmid: 9288409